Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardioangiologica 2016 February;64(1) > Minerva Cardioangiologica 2016 February;64(1):1-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLES   

Minerva Cardioangiologica 2016 February;64(1):1-8

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Effectiveness of a novel biodegradable polymer, sirolimus-eluting stent platform in percutaneous coronary intervention

Marcello DOMINICI 1, 2, Alessio ARRIVI 1, Marco BAZZUCCHI 1, Marcella DE PAOLIS 1, Caterina MILICI 1, Carlo BOCK 1, Attilio PLACANICA 1, Ludovico LAZZARI 1, Roberto DILETTI 2, 3, Enrico BOSCHETTI 1, 2

1 Interventional Cardiology Unit, S. Maria University Hospital, Terni, Italy; 2 University of Perugia/Terni School of Medicine, Terni, Italy; 3 Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands


PDF


BACKGROUND: The purpose of this registry is to report the immediate and long-term safety and efficacy of the Biotronik Orsiro stent in an unselected population during everyday practice.
METHODS: Between May 2012 and June 2013, 246 consecutive coronary angioplasty procedures were performed using at least one Orsiro drug-eluting stent, in 225 patients and 303 lesions.
RESULTS: Diabetes was present in 34.7% of patients. Procedures were non-elective percutaneous coronary intervention (PCI) in 17.1% of cases and acute coronary syndromes were 55.1%. Radial vascular access was used in 78% of cases, multivessel PCI was performed in 19.5% of the procedures. In 81.6% of cases lesions were B2/C type, 20.7% of procedures had bifurcation lesions. Procedural success was 99.6%. No acute thrombosis occurred. Clinical follow-up median period was 24.3 (±8.28) months and FU was available in 93.7% of patients. Death for any cause occurred in 11 patients (5.2%), 6 of them were non cardiac-related. Cardiac-related death rate was 2.4%. Two patients had in-stent restenosis. The overall target lesion failure rate was 3.3%.
CONCLUSIONS: This observational data regards our experience with Biotronik Orsiro stent in an unselected population. This initial data, although limited by a mainly clinical follow-up and restricted number of patients, confirms the good clinical performance of this sirolimus-eluting stent with a biodegradable polymer in everyday practice, including complex lesions, according to current larger studies in the literature.

top of page